Carlsmed (CARL) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Truist Securities | Maintained | Buy | $20.00 from $18.00 | Aug 6, 2026 |
| Needham | Initiated Coverage | Buy | $17.00 | Jul 1, 2026 |
| BTIG | Maintained | Buy | $23.00 | May 6, 2026 |
| Truist Securities | Maintained | Buy | $18.00 from $20.00 | Apr 15, 2026 |
| Goldman Sachs | Maintained | Buy | $17.00 from $19.00 | Apr 9, 2026 |
| BTIG | Maintained | Buy | $24.00 | Dec 15, 2025 |
| BTIG | Maintained | Buy | $24.00 from $21.00 | Nov 7, 2025 |
| Truist Securities | Maintained | Buy | $20.00 from $18.00 | Nov 7, 2025 |
| Truist Securities | Initiated Coverage | Buy | $18.00 | Aug 18, 2025 |
| Goldman Sachs | Initiated Coverage | Buy | $19.00 | Aug 18, 2025 |
| Piper Sandler | Initiated Coverage | Overweight | $18.00 | Aug 18, 2025 |
Frequently asked questions
Is CARL a buy, sell, or hold?
Analysts covering Carlsmed currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CARL?
On Aug 6, 2026, Truist Securities maintained Carlsmed at Buy with a price target of $20.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.